Combining JAK inhibitors with checkpoint inhibitors improves cancer immunotherapy response

FHS
June 20, 2024
7:26 pm

Because not all cancer patients respond to a leading type of cancer immunotherapy drug, known as an immune checkpoint inhibitor, scientists explored whether adding janus kinase (JAK) inhibitors – drugs that treat chronic inflammation – could help.

Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update – Biotech Investments

Issuer: Immunic AG / Key word(s): Miscellaneous 31.10.2024 / 11:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic, Inc. to

November 1, 2024

Diet and gut dysbiosis linked to rheumatoid arthritis

Review highlights how gut dysbiosis and dietary factors are linked to rheumatoid arthritis, influencing disease progression and inflammation. Researchers explore how specific diets may help

September 29, 2024

GLP-1 Revolution, Non-Traditional Delivery, and Telehealth Expansion

Guy Friedman, co-founder and CEO of SteadyMD The past few years have seen upheavals in healthcare, and 2024 so far shows no signs of breaking

February 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.